Unilife has entered into an agreement to develop and supply its targeted organ delivery device to a global pharmaceutical company.

Under the first phase of the program, Unilife will obtain $1.4m as development fees and from initial unit sales it will also receive revenue to conduct clinical trial for the device.

Unilife COO Ramin Mojdeh said their device enables the administration of a new molecule to a specific organ without surgery, helping to create a new class of therapies intended for direct organ delivery.